Exactly, thanks for that Snoball, they rushed it to a big trial without any real evidence for clinical efficacy, (they used a surrogate endpoint, always a dangerous practice) and then bombed big time. PRR on the other hand, have established clinical efficacy first, before launching Phase II/III. This is a credit to management that they are careful with shareholders money.
abagovomab vs oregovomab - facts ..., page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 29.5¢ | 28.5¢ | $738.8K | 2.546M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 75952 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 192050 | 5 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |